Hims & Hers Health short interest was 45.18% of the float on March 13th, according to new data we received from Benzinga. Short interest totaled 83,286,092 shares, which was a decrease of -1.98% from February 27th.
It is estimated that it would take 1.31 days for short sellers to buy back their shares, with current trading volumes.
Hims & Hers Health Insider Trading Activity
Hims & Hers Health insiders have traded $HIMS stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:
- OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 8 sales selling 102,080 shares for an estimated $3,949,395.
- MICHAEL CHI (Chief Operating Officer) has made 0 purchases and 4 sales selling 112,189 shares for an estimated $2,973,252.
- SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 6 sales selling 20,005 shares for an estimated $669,879.
- IRENE BECKLUND (PAO) has made 0 purchases and 2 sales selling 13,940 shares for an estimated $445,278.
- PATRICK HARRISON CARROLL (Chief Medical Officer) sold 10,021 shares for an estimated $367,870
- DEBORAH M. AUTOR (Chief Policy Officer) sold 7,054 shares for an estimated $258,952
- GARCIA ANDREA G PEREZ sold 2,500 shares for an estimated $97,925
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Hims & Hers Health Hedge Fund Activity
We have seen 235 institutional investors add shares of Hims & Hers Health stock to their portfolio, and 286 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FORERUNNER VENTURES MANAGEMENT, LLC removed 9,756,893 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $316,806,315
- FARALLON CAPITAL MANAGEMENT LLC removed 7,359,866 shares (-68.5%) from their portfolio in Q4 2025, for an estimated $238,974,849
- CAPITAL WORLD INVESTORS removed 4,460,282 shares (-23.7%) from their portfolio in Q4 2025, for an estimated $144,825,356
- RENAISSANCE TECHNOLOGIES LLC removed 4,278,843 shares (-47.0%) from their portfolio in Q4 2025, for an estimated $138,934,032
- MORGAN STANLEY removed 3,346,864 shares (-46.0%) from their portfolio in Q4 2025, for an estimated $108,672,674
- TIDAL INVESTMENTS LLC removed 2,759,789 shares (-96.5%) from their portfolio in Q4 2025, for an estimated $89,610,348
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,341,642 shares (-76.3%) from their portfolio in Q4 2025, for an estimated $76,033,115
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Hims & Hers Health Analyst Ratings
Wall Street analysts have issued reports on $HIMS in the last several months. We have seen 0 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Underperform" rating on 11/04/2025
To track analyst ratings and price targets for Hims & Hers Health, check out Quiver Quantitative's $HIMS forecast page.
Hims & Hers Health Price Targets
Multiple analysts have issued price targets for $HIMS recently. We have seen 11 analysts offer price targets for $HIMS in the last 6 months, with a median target of $24.0.
Here are some recent targets:
- Jonna Kim from TD Cowen set a target price of $23.0 on 03/27/2026
- Michael Cherny from Leerink Partners set a target price of $25.0 on 03/16/2026
- Glen Santangelo from Barclays set a target price of $29.0 on 03/11/2026
- George Hill from Deutsche Bank set a target price of $28.0 on 03/10/2026
- Allen Lutz from B of A Securities set a target price of $23.0 on 03/10/2026
- Daniel Grosslight from Citigroup set a target price of $24.0 on 03/10/2026
- Ryan MacDonald from Needham set a target price of $30.0 on 03/09/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
